Kingdon Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Kingdon Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-56,200	Closed	-$1.01M	–	145
2017 Q3	$1.01M	Buy	+56,200	New	+$940K	0.07%	105
2016 Q4	–	Sell	-452,200	Closed	-$7.53M	–	159
2016 Q3	$7.53M	Buy	452,200 +152,200	+51%	+$2.05M	0.35%	69
2016 Q2	$3.36M	Buy	+300,000	New	+$2.91M	0.18%	85
2015 Q4	–	Sell	-300,000	Closed	-$3.38M	–	147
2015 Q3	$3.38M	Buy	+300,000	New	+$3.67M	0.16%	97
2015 Q2	–	Sell	-1,400,000	Closed	-$13M	–	163
2015 Q1	$13M	Buy	+1,400,000	New	+$15.8M	0.55%	55
2014 Q4	–	Sell	-300,000	Closed	-$3.11M	–	174
2014 Q3	$3.11M	Sell	300,000 -100,000	-25%	-$1.31M	0.14%	131
2014 Q2	$6.47M	Sell	400,000 -360,000	-47%	-$4.79M	0.25%	113
2014 Q1	$12.3M	Sell	760,000 -440,000	-37%	-$6.26M	0.63%	51
2013 Q4	$14.9M	Buy	1,200,000 +800,000	+200%	+$8.03M	0.68%	42
2013 Q3	$4.38M	Buy	400,000 +200,000	+100%	+$2.14M	0.22%	129
2013 Q2	$1.62M	Buy	+200,000	New	+$1.35M	0.1%	172

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kingdon Capital Management's VNDA Position: Q2 2017 in Review

Kingdon Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2017, closing a stake of 288,392 shares — an estimated $4.04M sold.

Kingdon Capital Management first reported a position in VNDA in Q2 2013 and held it in 16 quarters. The position peaked at $35.2M in Q4 2014. 133 funds tracked by Wall St. Rank hold VNDA as of Q2 2017.

Kingdon Capital Management reported no remaining Vanda Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Kingdon Capital Management sold 288,392 Vanda Pharmaceuticals shares in Q2 2017, an estimated $4.04M.
Kingdon Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Kingdon Capital Management's Vanda Pharmaceuticals position peaked at $35.2M in Q4 2014.
133 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2017.

Based on Kingdon Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.